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Objective: Multiple solid cancers contain tertiary lymphoid organs (TLO). However, it is 
unclear whether they promote tumor rejection, facilitate tumor evasion, or simply whether 
they are a byproduct of chronic inflammation. We hypothesize that although chronic 
inflammation induces TLO formation, the tumor milieu can modulate TLO organization 
and functions in prostate cancer. Therefore, our study seeks to elucidate the cellular and 
molecular signatures in unique prostatectomy specimens from evanescent carcinoma 
patients to identify markers of cancer regression, which could be harnessed to modulate 
local immunosuppression or potentially enhance TLO function.
Methods: We used multicolor immunofluorescence to stain prostate tissues, collected 
at different stages of cancer progression (prostatic intraepithelial neoplasia, intermediate 
and advanced cancer) or from patients with evanescent prostate carcinoma. Tissues 
were stained with antibodies specific for pro-inflammatory molecules (cyclooxygenase 2, 
CXCL10, IL17), tumor-infiltrating immune cells (mature DC-LAMP+ dendritic cells, CD3+ 
T cells, CD3+Foxp3+ regulatory T cells (Treg), T bet+ Th1 cells, granzyme B+ cytotoxic 
cells), and stromal cell populations (lymphatic vessels, tumor neovessels, high endothe-
lial venules (HEV), stromal cells), which promote prostate tumor growth or are critical 
components of tumor-associated TLO.
results: Generally, inflammatory cells are located at the margins of tumors. Unexpectedly, 
we found TLO within prostate tumors from patients at different stages of cancer and in 
unique samples from patients with spontaneous cancer remission. In evanescent pros-
tate carcinomas, accumulation of Treg was compromised, while Tbet+ T cells and CD8 
T cells were abundant in tumor-associated TLO. In addition, we found a global decrease 
in tumor neovascularization and the coverage by cells positive for cyclooxygenase 2 
(COX2). Finally, consistent with tumor regression, prostate stem cell antigen was consid-
erably reduced in TLO and tumor areas from evanescent carcinoma patients.
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conclusion: Collectively, our results suggest that COX2 and Treg are attractive thera-
peutic targets that can be harnessed to enhance TLO-driven tumor immunity against 
prostate cancer. Specially, the presence of HEV and lymphatics indicate that TLO can be 
used as a platform for delivery of cell-based and/or COX2 blocking therapies to improve 
control of tumor growth in prostate cancer.
Keywords: tertiary lymphoid organs, high endothelial venules, homeostatic chemokines, evanescent prostate 
carcinoma, cyclooxygenase 2, prostatic intraepithelial neoplasia, follicular dendritic cells, peripheral node 
addressin
inTrODUcTiOn
Prostate cancer is the second malignancy diagnosed among men 
around the world (1), and it is the second cause of cancer death in 
United States (2). Fortunately, the mortality rate in patients with 
mild disease has decreased in the last 30 years after the introduc-
tion of prostate-specific antigen (PSA) screening. However, The 
American Cancer Society reported 180,980 new cases of prostate 
cancer and 26,120 deaths in 2016. This indicates that still better 
treatments are needed to improve survival for prostate cancer 
patients. For many years, Gleason score has been the classical tool 
to estimate progression and aggressiveness in prostate cancer and 
has helped to guide personalized therapy. Although it is based 
on detecting morphological changes in the prostate gland epithe-
lium, recent findings in the field of solid cancer suggests that most 
attention should be invested on searching for organized collec-
tions of tumor-infiltrating immune cells (T cells, B cells, dendritic 
cells), which are associated with improved survival prognosis and 
can reveal therapeutic targets for the clinical benefit of prostate 
cancer patients.
These organized collections of lymphocytes are known as 
tertiary lymphoid structures or tertiary lymphoid organs (TLO) 
and arise in peripheral tissues as a consequence of persistent 
inflammatory or antigenic stimulation (3–5). In seminal studies 
performed by Nancy Ruddle’s group, it was proposed that chronic 
inflammation was the driving force behind TLO formation 
(6, 7). Later, TLO were found in the liver and stomach of mice 
and in humans infected with Helicobacter pylori. In this particular 
setting, the stability of TLO was disrupted by reduction of the 
bacterial load after administration of antibiotics (8, 9). These 
findings suggest that antigens and recognition of pathogen- or 
damage-associated molecular patterns by immune cells are 
actively participating in TLO formation/organization, and that 
reduction in the local antigenic burden compromises TLO integ-
rity. Finally, although it is proposed that LT and HC chemokines 
are crucial for TLO formation and organization, several studies 
have recently revealed the contribution of additional inflam-
matory cytokines in TLO formation (10–14). In general, it is 
proposed that TLO have flexible programs, which are associated 
with protection (infectious disease, cancer) or that contribute 
to local pathology in inflammatory and autoimmune diseases 
(chronic obstructive pulmonary disease, rheumatoid arthritis, 
multiple sclerosis, Sjogren syndrome) (15–17). However, TLO 
functions can be both shaped by the local environment and 
influenced by temporal changes in disease- and tissue-specific 
signals. Interestingly, it is proposed that the immunosuppressive 
environment in tumors should interfere with TLO formation 
(18, 19). Thus, a better characterization of the local milieu will 
likely contribute to having a better understanding of the cellular 
and molecular factors that stabilize or disrupt TLO formation and 
organization. A basic understanding about the contexture of the 
complex cellular and molecular microenvironments surrounding 
TLO will provide the key to design therapeutic approaches that 
modulate TLO formation, organization, and stability for the ben-
efit of patients afflicted by inflammatory, autoimmune, infectious, 
and malignant diseases.
Tertiary lymphoid organs have been detected in solid cancers 
affecting a variety of tissues (breast, skin, lung, pancreas) (19–21). 
The assumption is that TLO are facilitating the induction of local 
immunity that participates in tumor clearance. Interestingly, 
although Di Carlo et al. reported presence of a TLO in the pros-
tate of healthy individuals (22), there is scarce information about 
the presence of TLO at different stages of prostate cancer (23). In 
the majority of solid tumors, infiltrating immune cells and TLO 
are preferentially located in the periphery of malignant tissue 
(24, 25). Unexpectedly, we detected tumor-associated TLO in the 
prostate of patients at different stages of disease, ranging from 
prostatic intraepithelial neoplasia (PIN) to late stages of prostate 
cancer. Importantly, they were even present in the prostate of a 
unique group of cancer patients that experienced spontaneous 
remission. This initial observation showed us that despite that 
TLO are present at different stages of cancer progression; their 
functions may be influenced by the spatiotemporal dynamic 
changes in the tumor environment. Thus, the central goal of this 
study was focused on defining the cellular and molecular changes 
in the tumor environment around TLO, which might be associ-
ated with tumor progression or regression and that are likely 
modulating TLO functions.
MaTerials anD MeThODs
Prostate Tissue and Patient information
Prostate specimens were collected with written consent of patients 
and after approval by the Ethical Committee of the National 
Institute of Medical Sciences and Nutrition “Salvador Zubiran.” A 
total of 27 prostate specimens (14 biopsies and 13 prostatectomy 
specimens) from 17 patients were included in our retrospective 
study. Interestingly, four patients who were initially diagnosed 
with adenocarcinoma (biopsy) had no evidence of tumor growth 
after subsequent collection of prostatectomy specimens—a 
histopathological finding commonly recognized by urologists 
as evanescent prostate carcinoma (26). Importantly, none of the 
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patients were treated with any medication before prostatectomy, 
ruling out the possibility that cancer therapy caused tumor regres-
sion. We divided our patients in two cohorts: evanescent (n = 4) 
and non-evanescent prostate carcinoma (n = 13). Additionally, 
patients in the non-evanescent cohort were classified according 
to prostate cancer aggressiveness (Gleason grading system) (27) 




The primary antibodies were as follows: goat anti-human CD105 
(AF1097, R&D Systems), rabbit anti cyclooxygenase 2 (GTX15191, 
GeneTex), mouse anti-human CD68 (clone PG-M1, GeneTex), 
goat anti-CD3 epsilon (clone M-20, Santa Cruz Biotechnology), 
rabbit anti-T bet (H-210, Santa Cruz biotechnology), rat anti-
human Foxp3 (PCH101, eBioscience), goat-anti proliferating cell 
nuclear antigen (PCNA) (clone C-20, Santa Cruz Biotechnology), 
mouse anti-human Ki-67 (clone MIB-1, Dakocytomation), rabbit 
anti-human CD8 (clone SP16, Thermo Fisher Scientific), mouse 
anti-human CD20 (clone L-26, Abcam), rabbit anti-human 
PD-L1 (Invitrogen, PA5-28115), rabbit anti-IL17 (H-132, Santa 
Cruz Biotechnology), mouse anti-human CD21 (clone 2G9, 
Thermo Fisher Scientific), rat anti-peripheral node addressin 
(clone MECA-79, BD Pharmigen), rabbit anti-human CD138 
(RB-9422-P1, Thermo Fisher Scientific), mouse anti-podoplanin 
(clone D2-40, GTX31231, GeneTex), rabbit anti-granzyme B 
(clone EPR8260, Abcam), rat anti-human DC-LAMP (clone 
1010E1.01, Novus Biologicals), rabbit anti-human prostate stem 
cell antigen (PSCA) (GTX15168, GeneTex), rabbit anti-human 
CXCL10 (GTX31176, GeneTex), biotin-mouse anti-smooth 
muscle actin (clone 1A4, Thermo Fisher Scientific), and mouse 
anti-human plasma cell (clone LIV3G11, Thermo Fisher 
Scientific).
Secondary Antibodies and Streptavidin
The secondary antibodies and streptavidin were as follows: 
Alexa Fluor 568-donkey anti-goat Ig G (H + L) cross adsorbed 
(A-11057, Thermo Fisher Scientific), F(ab)2 FITC-donkey anti-
rabbit (711-096-152, Jackson ImmunoResearch Laboratories), 
F(ab)2 biotin-donkey anti mouse (715-066-150, Jackson 
ImmunoResearch Laboratories), F(ab)2 biotin-donkey anti-rat 
Ig G (712-066-150, Jackson ImmunoResearch Laboratories), 
Cy3-goat anti-rat Ig M (112-166-075), and Cy5-streptavidin 
(405209, Biolegend).
immunofluorescent Detection of cell 
infiltrates in Paraffin Prostate sections
The 5-µm paraffin tissue sections were first incubated at 60°C 
for at least 1  h to melt paraffin, followed by quick transfer 
into xylenes. After removing paraffin, slides were hydrated by 
sequential immersion into absolute alcohol, 95% alcohol, 75% 
alcohol, and finally thoroughly washed with deionized water. 
Antigens were unmasked by boiling slides for 30 min in antigen 
retrieval solution (S1699, Dako laboratories). To prevent non-
specific binding, sections were incubated for 30  min with 5% 
normal donkey serum (017-000-121, Jackson ImmunoResearch 
Laboratories). Next, primary antibodies were added to prostate 
sections and incubated overnight at room temperature. To reveal 
primary antibodies, slides were incubated at room temperature 
for 2 h with fluorescent secondary antibodies. Sections were incu-
bated with Cy5-conjugated streptavidin (405209, eBioscience) 
for one extra hour at room temperature to detect biotinylated 
antibodies. Finally, sections were washed with PBS and mounted 
with Vectashield mounting medium with DAPI (H-1200, Vector 
Laboratories). Representative pictures were acquired with a Zeiss 
Axioplan 2 microscope and recorded with a Hamamatsu camera 
after performing morphometric analysis.
Morphometric analysis of lymphoid  
and B cell Follicles
Lymphoid follicles (LF) were defined as organized and compact 
collections of lymphocytes that were readily detected in H&E 
sections from prostatectomy specimens. For morphometric 
analysis of LF, all organized lymphocytic structures in individual 
prostatectomy specimens were enumerated and outlined with 
automated tools of the Zeiss Axioplan software to calculate the 
average number and size of LF. LF dimensions are expressed in 
square microns.
area covered by cD105+ Vessels, cOX2+, 
Psca+, and cXcl10+ cells, in  
TlO-associated Microenvironments  
and Tumor areas lacking TlO
Nine 200× pictures were automatically stitched with the mosaic 
feature of the Zeiss Axioplan 2 microscope software (mosaic 
pictures: 3 × 3 200× pictures). TLO were placed in the center of 
the mosaics to have a global view of surrounding tumor micro-
environment. We acquired JPGE mosaic pictures of all TLO areas 
or five to eight mosaic pictures from tumor areas without TLO 
in each prostatectomy section, and measured the area occupied 
by CD105+ vessels, COX2+, PSCA+, and CXCL10+ cells in a 
mosaic picture with NIH ImageJ software. Measurements using 
ImageJ software were blindly performed by two independent 
evaluators and using the same parameters for all the pictures. The 
percentage of area covered by CD105+ vessels, COX2+, PSCA+, 
and CXCL10+ cells in panoramic mosaics was calculated by 
dividing the area occupied by CD105+ vessels or positive cells 
(pixels2), by the total area of the panoramic mosaic (mosaic 
area = 1.043 µm2 = 10,034,185 pixels2).
Quantitation of granzyme B+ cells, 
regulatory T cells (Treg), and Dc laMP+ 
cells in Tumor-associated TlO
DC LAMP, granzyme B, and CD8 T cells were counted in T cell 
areas of all TLO contained in individual prostate sections (200× 
random fields/section). In addition, the same populations were 
enumerated in five to eight random 200× fields per tissue section 
in areas with signs of epithelial cell transformation. We calculated 
the relative frequency of CD3+Foxp3+ (Treg/Treg + Tbet × 100) 
and CD3+Tbet+ (Tbet/Treg  +  Tbet  ×  100) in TLO. We also 
determined the ratio between Tbet+ T cells and Treg populations 
inside TLO to have an idea about the dynamic changes in those 
TaBle 1 | Demographic and clinical features of patients with prostatic carcinoma.
evanescent carcinoma (n = 4) non-evanescent carcinoma (n = 13)
Age at diagnosis 66.3 ± 6.8 65.9 ± 5.6
Presence of prostatic intraepithelial neoplasia (yes/no) 0 (0%)/4 (100%) 9 (69%)/4 (31%)
Gleason sum (6/7/8/9/10) 4/0/0/0/0 2/5/2/3/1
Prostate-specific antigen at diagnosis 12.2 ± 6.1 83.5 ± 252.2
Extension of neoplasm in biopsy/prostatectomy (5) 1 ± 0 22.5 ± 24
Multicentricity (yes/no) 0 (0%)/4 (100%) 3 (23%)/10 (67%)
Perineural invasion (yes/no) 0 (0%)/4 (100%) 4 (31%)/9 (69%)
Necrotic tissue in tumor (yes/no) 0 (0%)/4 (100%) 4 (31%)/9 (69%)
Margins free of disease (yes/no)a NA 4 (31%)/9 (69%)
Pathologic TNM stage (IIA/IIB/IIIIV)a NA 1 (11%)/3 (33%)/4 (45%)/1 (11%)
Clinical TNM stage (I/IIA/IIB/III/IV) 10/0/0/0/0 1 (7.5%)/4 (31%)/1 (7.5%)/3 (23%)/4 (31%)
aInformation not available for patients who did not undergo a prostatectomy or whose prostatectomy did not contain tissue consistent with prostatic carcinoma.
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T  cell populations during cancer progression/regression, and 
determined the correlation between the number of Treg and TLO 
in prostatectomy specimens from intermediate and advanced 
prostate cancer patients.
statistics
Comparisons between two groups were performed with two-
tailed T test. Correlation was calculated with Pearson’s coefficient. 
Percentage of cancer-free patients after cancer diagnosis was 
estimated by Kaplan–Meier method, and significant differences 
among the groups were calculated by using long-rank (Mantel–
Cox) test. Differences with a p value ≤0.05 were considered 
statistically significant.
resUlTs
a Unique cohort of Prostate cancer 
Patients experienced spontaneous 
Disease remission
We collected 27 histological samples from 17 patients diagnosed 
with non-evanescent (intermediate and advanced grades) and 
evanescent prostate carcinoma. Patients with non-evanescent 
prostate carcinoma displayed clear histological signs of PIN 
(69%), considerable cancer aggressiveness (50% patients 
with a Gleason score of 8 and above), increased levels of PSA 
(83.5 ±  252.2), and showed clinical and pathological features 
of cancer progression (TNM stages: IIA to IV). By contrast, 
patients with evanescent carcinoma do not have any signs of 
prostate intraepithelial neoplasia (0%), had considerably lower 
PSA levels (12.2 ± 6.1), cancer was significantly less aggressive 
(6.0 ± 0.0), and did not have any evidence of clinical or pathologi-
cal changes in the prostate (Table 1). We followed the patients 
for a maximal period of 179 months. As expected, we found that 
none of the patients diagnosed with advanced carcinoma were 
cancer free at 52 months post-diagnosis. By contrast, 33.3% of 
patients at intermediate stages of prostate cancer remained cancer 
free until the end of our retrospective study (179 months after 
cancer diagnosis). Interestingly, 100% of patients with evanescent 
prostate carcinoma were disease free at the conclusion of the 
study (Figure  1). Evanescent prostate carcinoma patients had 
evidence of prostate cancer in an initial biopsy but did not show 
any histological features of adenocarcinoma after collection of 
prostatectomy specimens for confirmatory diagnosis. Thus, we 
considered those prostatectomy specimens from patients with 
evanescent prostate cancer unique, because they could reveal 
therapeutic targets that can be harnessed to design novel prostate 
cancer therapies.
Tumor-associated lF are Present in the 
Prostate during cancer Progression  
and in Patients experiencing  
spontaneous cancer remission
Tertiary lymphoid organs are induced in the context of chronic 
inflammation, autoimmunity, and cancer (24, 25) and are usually 
absent in healthy tissues. However, TLO have been previously 
described in the prostate of healthy individuals (22). Thus, con-
sidering the relevance of TLO in the positive prognosis of other 
solid malignancies (19), we examined the presence of organized 
collections of tumor-infiltrating lymphocytes in biopsies and 
prostatectomy specimens from patients with PIN, intermediate 
and advanced cancer, as well as in patients with evanescent carci-
noma. Although we easily identified lymphocytic structures at all 
stages of prostate cancer (Figures 2A–C), and in prostatectomy 
specimens from patients with evanescent prostate carcinoma 
(Figure  2D), their sizes were very heterogeneous. Organized 
lymphocyte clusters were preferentially located inside tumors, 
in close proximity to glandular epithelium and blood vessels 
(Figures 2A,B). To define the average size of lymphocytic accumu-
lations in prostatectomy specimens from PIN and prostate cancer 
patients, we outlined all TLO contained in individual sections with 
an automated tool of the Zeiss Axioplan software. TLO in PIN 
samples were significantly bigger (29,858.51 ± 23,608.22 µm2) than 
those in intermediate (16,218.62 ± 11,337.79 µm2, p < 0.0001), 
advanced (9,539.11 ±  6,608.31  µm2, p =  0.0027), and evanes-
cent carcinoma (Eva Ca; 10,843.25 ±  5,274  µm2, p <  0.0001) 
(Figure 2E). Additionally, we found a directly proportional cor-
relation between the number and the size of LF at intermediate 
and advanced stages of prostate carcinoma (r2 = 0.7501, p = 0.05) 
(Figure 2F). Our results are indicating that either a decline in the 
tumor antigen load or the immunosuppressive tumor environ-
ment is having a negative impact on the formation or stability of 
LF (19, 22, 24, 25).
FigUre 1 | a unique cohort of prostate cancer patients experienced 
spontaneous cancer remission. Different groups of prostate cancer 
patients were classified according to their systemic levels of prostate 
antigen-specific antigen and histopathological features (biopsies or 
prostatectomy specimens) and were monitored for a maximal period of 
179 months (approximately 15 years). 100% of patients were cancer free in 
low and evanescent carcinoma cohorts, compared to the rapid development 
of active malignant disease in patients with advanced prostate cancer 
(median for cancer development: 13.5 months), and the moderate cancer 
progression at intermediate stages of prostate cancer (median for cancer 
development: 121 months). Percentage of tumor-free patients was calculated 
by long rank test (Mantel–Cox). Differences in tumor development among the 
groups were statistically significant (p = 0.0303). n = 17 prostate cancer 
patients and 27 prostate specimens.
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Tumor-associated TlO in Prostate cancer 
contain Follicular Dendritic cells (FDc), 
and Proliferating B cells and cD8 T cells
It has been previously reported that the presence of TLO with 
dense B cell follicles and enriched with CD8 T cells correlates with 
favorable prognosis in cancer patients (18, 19). Thus, we first ana-
lyzed the cellular composition in tumor-associated TLO by stain-
ing prostatectomy specimens with antibodies specific for PCNA, 
CD8, and CD20. We also stained serial sections with antibodies 
against CD21 to visualize FDC and to get an idea of the effect of 
activated B cells on stromal cells. We found that prostate tissues 
from patients with PIN and prostate cancer have CD20+ B cells 
follicles with central FDC networks, which were surrounded 
by T  cells areas populated by CD8 T  cells (Figures  3A–H). 
Consistent with previous reports (18); we confirmed that TLO 
were very heterogeneous, even in the same prostate section. In 
PIN and intermediate prostate cancer, B cell follicles were loosely 
organized and contained few proliferating B cells (Figures 3A,B). 
In agreement with poor B  cell activation, FDC networks were 
small in prostate tumors from patients with PIN and intermedi-
ate cancer (Figures  3E,F). Interestingly, some TLO in prostate 
tumors from patients with advanced disease contained many 
PCNA+CD20+ B cells (Figure 3C) and large CD21+ FDC networks 
(Figure 3G), indicating that despite the suppressive environment, 
activated B  cells were still able to induce the differentiation of 
tumor-associated stromal cells into FDC. By contrast, prostate 
sections from patients with evanescent carcinoma had less 
PCNA+CD20+ B cells (Figure 3D) and contained well-organized 
FDC networks (Figure 3H). We observed similar staining pattern 
with Ki67 and PCNA in consecutive serial sections of inflamed 
tonsil and confirmed that in certain areas of the prostate tumor 
there was a permissive microenvironment, which supported 
immune cell proliferation (Figure S1 in Supplementary Material). 
Thus, it is likely that either local release of immunogenic prostate 
antigens (28) or immunologically permissive environments in 
certain areas of prostate tumors might still support local immune 
cell activation and thus contribute to stabilize TLO.
Previously, we showed that IL17 is critical at early stages of 
TLO formation in lungs from neonate mice instilled with LPS 
(10). Therefore, we decided to determine whether T cell-derived 
IL-17 participates in the formation of TLO in prostate cancer. Even 
though we did not find CD3+IL17+ T cells around TLO, we occa-
sionally observed a few CD3−IL17+ cells outside of B cell follicles in 
prostatectomy specimens from patients with evanescent carcinoma. 
According to their location, they are probably IL17-producing type 
3 innate lymphoid cells, which have been previously detected in 
close association to TLO in human lung cancer (29).
Next, we enumerated CD8 T cells in TLO and tumor areas. Of 
note, CD8 T cells were approximately three times more numer-
ous in TLO areas, compared to sites of malignant transformation 
(Figures  4A,B). Morphometric analysis revealed that CD8 
T cells in TLO were significantly more abundant in PIN patients 
(56.45 ± 9.19), compared to numbers of CD8 T cells in TLO from 
intermediate (35.16 ±  8.53, p <  0.0001), advanced (20 ±  5.41, 
p < 0.0001), and evanescent prostate carcinoma (37.77 ± 10.61, 
p = 0.0005) (Figure 4A). Remarkably, CD8 T cells were signifi-
cantly increased in TLO of evanescent carcinoma tumors, com-
pared to CD8 T cells in TLO from advanced carcinoma patients 
(p =  0.0002). Furthermore, it was clear that CD8 T  cells were 
considerably enriched in tumor areas of evanescent carcinoma 
patients, relative to CD8 T  cell numbers in PIN (19.18 ±  2.4, 
p < 0.0001), intermediate (18.07 ± 1.07, p < 0.0001), and advanced 
prostate carcinoma (12.35  ±  1.27, p  <  0.0001) (Figure  4B). 
Consistently, CD8 T cells were significantly reduced in TLO and 
tumor areas from patients at advanced stages of prostate cancer. 
Our results are indicating that spontaneous tumor regression 
in evanescent prostate cancer patients might be associated with 
enhanced ability of TLO to prime, recruit, or retain CD8 T cells 
(18, 19).
changes in neovascularization and 
cyclooxygenase 2 in TlO and Prostate 
Tumor areas
It is known that tumors induce angiogenesis to grow and 
metastasize to distal organs (30–32). Based on the relevance of 
blood vessels in tumor growth, we evaluated the percentage of 
area covered by tumor vasculature in PIN and prostate cancer 
samples by immunofluorescence. Prostate sections were stained 
with antibodies specific for CD105 (endoglin), which is currently 
considered a good marker for proliferating endothelial cells and 
newly forming tumor vessels (33–36). Our immunofluorescence 
stain showed oval and cuboidal shaped endothelial cells in TLO 
vessels, indicating CD105 antibodies are labeling both blood 
vessels and high endothelial venules (HEV). In PIN samples, 
a few CD105+ HEV-like vessels were located in the center of 
TLO (Figure  5A), while in a few tumor areas, CD105+ vessels 
displayed an abnormal morphology and disorganized pattern 
(Figure  5E). In TLO areas, CD105+ HEV were small and less 
FigUre 2 | Tumor-associated tertiary lymphoid organs (TlO) are present during prostate cancer progression and remission. The 5-µm thick paraffin 
sections were stained with H&E, and all lymphoid follicles (LF) were enumerated and measured in a blinded manner. (a–D) After calculating the average size of LF, 
representative 200× magnification pictures from prostatectomy specimens of patients at different stages of cancer progression and patients with evanescent 
prostate carcinoma were taken with a Zeiss Axioplan microscope. Tumor-associated TLO were located in close proximity to epithelium (black arrows) and blood 
vessels (black arrowheads). Scale bar represents 100 µm. All LF in individual prostatectomy specimens were outlined with an automated tool of the Zeiss Axioplan 
microscope. (e) Average size of LF was calculated for prostatic intraepithelial neoplasia (PIN), intermediate (Int), advanced (Adv), and evanescent prostate carcinoma 
(Eva Ca). n = 28–97 measurements per group. (F) Significant correlation between number and size of TLO size during cancer progression is shown (Pearson, 
r2 = 0.7501, p = 0.05). Bar represent mean ± SEM. Statistically significant differences (*p ≤ 0.05, **p ≤ 0.005, ****p < 0.0001) were calculated by using two-tailed 
Student’s t-test with GraphPad Prism.
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abundant (Figure 5B), contrasting with the increased vasculari-
zation seen in multiple tumor areas from intermediate carcinoma 
patients (Figure 5F). Unexpectedly, we still found CD105+ HEV 
in TLO from patients with advanced carcinoma, but they were 
small and have a flat appearance (Figure 5C). At a glance, CD105+ 
vessels in tumor areas looked similarly abundant in prostatec-
tomy specimens from intermediate and advanced prostate cancer 
(Figures 5F,G). Finally, the area covered by CD105+ vessels was 
comparable in TLO and tumor areas from patients with evanes-
cent carcinoma, and the blood vessel morphology and spatial 
arrangement were better preserved in both micro anatomical 
locations (Figures 5D,G).
Cyclooxygenase 2 (COX2) is an inducible enzyme that par-
ticipates in the production of prostaglandin E2—a bioactive lipid 
with multiple immunomodulatory properties (37). In cancer, 
COX2 plays an important role on tumor-associated immune sup-
pression, tumor-driven angiogenesis, and proliferation/renewal 
of cancer stem cells (38–40). Thus, we analyzed the morphology, 
localization, and distribution of COX2-producing cells in areas 
containing TLO (Figures 5A–D) and tumor areas (Figures 5E–H). 
According to their cell morphology and spatial location, we found 
that COX2 was expressed by a variety of tumor-infiltrating cells 
including cuboidal epithelial cells (Figures 5E–H), oval-shaped 
endothelial cells (Figures 5C,D), spindle-shaped fibroblasts, and 
FigUre 3 | il17 production, B cell activation, and cD8 T cell accumulation are evident in prostate tumor-associated tertiary lymphoid organs (TlO). 
The 5-µm thick paraffin sections were stained with antibodies against proliferating cell nuclear antigen (PCNA, red), CD8 (green), and CD20 (white) to identify B cells 
and CD8 T cells in tumor-associated TLO. Serial sections were stained with antibodies against CD21 (red), IL17 (green), and CD3 (white). Representative 200× 
magnification pictures from the same TLO areas showed in H&E stains were taken with a Zeiss Axioplan Microscope and recorded with a Hamamatsu Camera. 
(a,e) Well-populated B cells follicles with small numbers of small proliferating B cells, small follicular dendritic cell (FDC) networks, and intrafollicular CD8 T cells are 
appreciated in prostatic intraepithelial neoplasia (PIN) prostatectomy specimens. (B,F) Large PCNA+CD20+ B blasts, and CD8 T cells interspersed inside B cell 
follicles are detected in prostate samples from patients at intermediate stages of cancer. (c,g) A germinal center with a concentric FDC network, containing multiple 
large proliferating B blasts and surrounded by CD8 T cells was found inside some TLO of prostatectomy specimens from patients afflicted by advanced cancer. 
(D,h) Although proliferating B cells are notably reduced, B cell and CD8 T cells are still organized in TLO from evanescent prostate cancer patients. Yellow arrows 
point to proliferating B cells, while white arrow is depicting a proliferating CD8 T cell. Scale bars represent 100 µm.
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immune cells. In TLO areas, COX2 antibodies labeled CD68+ mac-
rophages (Figures 5A,C) and CD68− immune cells inside B cell 
follicles (Figure 5C). It is likely that some of the CD68−COX2+ 
cells could be B cells, monocytes or monocyte-derived myeloid 
suppressor cells (41, 42). Sporadically, we also found COX2+ 
cells with hypersegmented nuclei morphology, which is typical 
for neutrophils or neutrophil myeloid-derived suppressor cells 
(43, 44).
FigUre 4 | enumeration of cD8 T cells in tertiary lymphoid organs (TlO) and tumor areas of prostate cancer. CD8 T cells were counted in all TLO 
contained in individual prostatectomy specimens or in five to eight randomly selected tumor areas lacking TLO (200× magnification). (a) Average number of CD8 
T cells inside TLO and (B) average number of CD8 T cells in tumor regions are shown. n = 10–19 measurements/patient cohort. Bars represent mean ± SEM. 
Statistically significant differences (***p ≤ 0.0005, ****p < 0.0001) were calculated by using two-tailed Student’s t-test with GraphPad Prism.
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Next, we calculated percentage of coverage by CD105+ blood 
vessels and COX2+ cells in TLO-associated microenvironments 
and tumor areas with equal dimensions, as explained in Section 
“Materials and Methods.” The percentage of area covered by 
CD105+ vessels was approximately two times larger in TLO 
from PIN patients (0.43 ± 0.33%), compared with area occupied 
by CD105+ vessels in TLO from intermediate (0.2  ±  0.16%, 
p = 0.0102) and evanescent carcinoma patients (0.25 ± 0.11%, 
p = 0.0401) (Figure 6A). In comparison to PIN (0.34 ± 0.12%), 
areas occupied by CD105+ vessels in regions of epithelial cell 
transformation were significantly larger in prostate sections 
from intermediate (0.88  ±  0.52%, p  =  0.0006), advanced 
(0.75 ± 0.15%, p < 0.0001), and evanescent prostate carcinoma 
patients (0.56 ± 0.16%, p = 0.0016) (Figure 6B).
In addition, we found that percentage of area covered by 
COX2+ cells in TLO was significantly smaller in prostatectomy 
specimens from evanescent carcinoma patients (0.22 ± 0.07%), 
compared to areas occupied by COX2+ in prostate sections from 
PIN (0.73 ±  0.27%, p <  0.0001), intermediate (0.44 ±  0.24%, 
p =  0.0017) and advanced carcinoma patients (0.76 ±  0.18%, 
p < 0.0001) (Figure 6C). Percentage of COX2+ cell coverage in 
tumors from evanescent prostate carcinoma was even signifi-
cantly smaller than percent of area covered by COX2+ cells in PIN 
and prostate cancer samples (0.13 ± 0.06, p < 0.0001 vs all patient 
cohorts). In tumor areas, percentage of coverage by COX2+ cells 
was significantly higher in intermediate (1.31 ± 0.51%, p < 0.0001) 
and advanced prostate carcinoma (1.41 ±  0.31%, p <  0.0001), 
compared to PIN (0.40  ±  0.13%). (Figure  6D). Overall, our 
results show that COX2 is an important player in tumor-driven 
suppression, which is likely impairing TLO-derived protective 
immunity during cancer progression.
PD-l1+ inflammatory cells accumulate 
Preferentially at Tumor areas in during 
Prostate cancer Progression
It was recently discovered that PGE2 induces PD-L1 expres-
sion on myeloid suppressor cells contributing to local tumor 
immunosuppression. Thus, we decided to analyze changes in 
PD-L1 expression during prostate cancer progression or regres-
sion. We detected PD-L1+ cells in TLO areas from patients with 
PIN and from prostatectomies collected at different stages of 
prostate cancer progression (Figures 7A–C). By contrast, TLO 
from patients with evanescent prostate carcinoma contained 
less PD-L1+ cells (Figure 7D). In tumor areas, we detected few 
PD-L1+ cells in prostatectomies from PIN (Figure  7E) and 
evanescent prostate carcinoma samples (Figure  7H). It was 
evident that PD-L1+ were more numerous in tumor areas of 
patients affected by intermediate and advanced prostate cancer 
(Figures 7F,G). Thus, it seems that prostate tumor microenvi-
ronment is either attracting suppressive cells that express PD-L1 
or inducing the expression of PD-L1 in tumor-infiltrating cells.
Dynamic changes in cD3+Tbet+ Th1 cells 
and cD3+Foxp3+ Treg inside TlO  
correlate with cancer Progression and 
spontaneous Prostate cancer regression
Tertiary lymphoid organs induce protective immunity at 
peripheral locations (45–47). However, we were perplexed about 
the similar size of tumor-associated TLO in advanced and eva-
nescent prostate carcinoma samples. Because PGE2 modulates 
Th1 immunity and support differentiation and functions of 
Treg—cells key in modulating inflammation, adaptive immunity, 
and TLO organization (48–52), we focused on detecting Tbet+ 
T cells and Foxp3+ Treg by immunofluorescence in prostatectomy 
specimens. We observed that CD3+Foxp3+ and CD3+Tbet+ 
T cells accumulated in T cell areas of TLO, and even we could 
occasionally find Th1 and Treg establishing close interactions 
(Figures  8A–C). Massive accumulation of CD3+Tbet+ T  cells 
was obvious in TLO from evanescent prostate carcinoma patients 
(Figure 8D).
Consistent with our predictions, the percentage of CD3+Foxp3+ 
T  cells was higher in TLO from advanced prostate carcinoma 
(22.83 ± 7.83%) and PIN samples (24.4 ± 28.56%), compared to 
their frequencies in TLO from intermediate (15.28 ± 6.52%, PIN 
vs intermediate: p = 0.0287) and evanescent carcinoma patients 
(15.42  ±  5.02%) (Figure  8E). Conversely, higher percentage 
of CD3+Tbet+ cells was detected in TLO from evanescent car-
cinoma sections (98.3 ±  2.86%), compared to their percentage 
in TLO from PIN (23.57 ±  12.48%, p =  0.0001), intermediate 
(37.41 ±  8.35%, p <  0.0001) and advanced prostate carcinoma 
patients (34.33 ±  8.35%, p =  0.0080) (Figure  8F). CD3+Tbet+ 
T cells were enriched in TLO from evanescent prostate carcinoma 
FigUre 5 | spatiotemporal changes in tumor vascularization and cOX2 coverage at different stages of prostate cancer progression/regression.  
The 5-µm thick paraffin serial sections were stained with antibodies against endoglin (CD105, red), cyclooxygenase 2 (COX2, green), and CD68 (white).  
(a–D) Representative 200× pictures are showing changes in vascularization and COX2 expression in tertiary lymphoid organs (TLO), or (e–h) tumor areas. (a) 
CD105+ vessels, CD68+COX2+ macrophages, and CD68−COX2+ cells are detected in TLO from prostatic intraepithelial neoplasia (PIN) patients. (B) Smaller CD105+ 
vessels and CD68−COX2+ cells are located on the border of TLO from intermediate prostate cancer patient. (c) In a prostatectomy specimen from advanced 
carcinoma patient, CD105+ vessels with cuboidal morphology are located outside TLO, while numerous CD68−COX2+ cells are found in the center of a TLO. (D) 
Oval-shaped and spindle-shaped COX2+ cells are located on the border of a TLO. (e) Vascularity and COX2+ epithelial cells are modestly increased in tumor areas 
from PIN patients. (F,g) Abundant blood vessels with abnormal morphology and aberrant organization were located in close proximity to strongly labeled COX2+ 
transformed epithelium in tumors of intermediate and advanced prostate cancer patients. (D,h) Preserved vascular morphology and organization,  
as well as reduced COX2+ density were observed in TLO and tumor areas from patients with spontaneous prostate cancer regression. CD105+ vessels with a high 
endothelial venule-like morphology were detected in TLO from patients at late stages of prostate cancer (white asterisk). Representative 200× magnification pictures 
of TLO and tumor areas were taken with a Zeiss Axioplan Microscope and recorded with a Hamamatsu Camera. Scale bars represent 100 µm.
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patients, as shown by the significant increase in the ratio between 
Tbet+ and Foxp3+ T cells (6.47 ± 1.76), relative to PIN (1.1 ± 0.7, 
p = 0.0006), intermediate (2.25 ± 0.76, p < 0.0001), and advanced 
prostate carcinoma patients (1.63 ± 0.67, p < 0.0001) (Figure 8G). 
We also enumerated Treg and Tbet T  cells in prostate paren-
chyma, around blood vessels, and in intraepithelial areas, but 
we did not find any trend between cancer stages and changes in 
the accumulation of Tbet+ or Foxp3+ T cells. We only detected a 
FigUre 6 | Percentage of cD105+ blood vessel and cOX2+ cell coverage during prostate cancer progression and regression. To calculate the 
percentage of CD105+ vessel and COX2+ cell coverage in areas with tertiary lymphoid organs (TLO), lymphocytic structures were placed in the center, and 3 × 3 
mosaic pictures were taken with the Zeiss Axioplan microscope (1.043 mm2). Panoramic mosaic pictures were taken for all the TLO contained in individual 
prostatectomy specimens. In areas lacking TLO and containing transformed epithelium, we measure the density for CD105+ vessels and COX2+ cells in three to five 
random fields/prostatectomy. (a) The percentage of CD105+ blood vessel coverage was smaller in prostate cancer and evanescent carcinoma, compared to 
prostatic intraepithelial neoplasia (PIN). (B) In tumor areas, percentage of CD105+ vessel coverage was the highest at intermediate and advanced stages of prostate 
cancer, compared to their percentage of coverage in PIN and evanescent prostate carcinoma samples. n = 7–35 panoramic mosaics/patient cohort to calculate 
CD105+ vessel coverage. (c) In TLO, percentage of COX2+ cell coverage was higher in advanced prostate carcinoma, compared to area covered by COX2+ cells in 
samples from intermediate and evanescent prostate carcinoma patients. (D) Areas occupied by COX2+ cells were significantly larger at intermediate and advanced 
stages of prostate cancer, while area covered by COX2+ cells was considerably smaller in evanescent prostate carcinoma, even when compared to percentage of 
area covered by COX2+ cells in PIN samples. n = 7–34 panoramic mosaic/group to calculate COX2+ cell coverage. Differences between groups were calculated by 
using two-tailed, paired, or unpaired Student’s t-test, using GraphPad Prism. Bar represent mean ± SEM. Statistically significant differences: *p ≤ 0.05, **p ≤ 0.005, 
***p ≤ 0.0005, ****p < 0.0001.
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significant increase in the number of Treg in all tumor microen-
vironments of patients at advanced stages of prostate cancer (data 
not shown). Finally, there was a significant inverse correlation 
between the number of TLO and the number of Treg (r2 = 0.8129, 
p =  0.0183) (Figure  8H). Thus, our results are suggesting that 
numerical changes in Treg and Th1  cells inside TLO are more 
directly associated with prostate cancer progression or spontane-
ous regression and are likely showing that besides the role of Treg 
in modulating local inflammation and adaptive immunity, they 
are possibly affecting TLO organization during prostate cancer 
progression (51, 52).
impaired accumulation of granzyme B+ 
cells correlates with reduced numbers  
of Mature Dc-laMP+ antigen-Presenting 
cells (aPc) and small heV in advanced 
Prostate carcinoma
To identify additional immune cells that are key in tumor immu-
nity, we counted granzyme B+ CD8 T cells and mature dendritic 
cell lysosomal-associated membrane protein (DC-LAMP, 
CD208) APC inside TLO. We found increased numbers of 
mature DC-LAMP+ cells in PIN (6.27  ±  3.25), compared to 
their numbers in advanced (3.66 ±  1.63, p =  0.0445) and eva-
nescent prostate carcinoma (4.44 ± 2.0, p = 0.0356) (Figure 9A). 
Numbers of granzyme B+ cells showed a similar trend, with 
significantly higher numbers in PIN (4.9  ±  2.42), compared 
to advanced (2.6  ±  1.67) and evanescent prostate carcinoma 
(2.83 ± 1.85, p = 0.0149) (Figure 9B). Unexpectedly, both popu-
lations were significantly reduced in prostatectomy specimens 
from patients with advanced and evanescent prostate carcinoma 
(Figures  9A,B). Thus, it is likely that poor accumulation of 
mature APC in TLO during advanced prostate carcinoma may be 
linked to impaired Th1 priming and compromised generation or 
recruitment of granzyme B+ cells, while their apparent reduction 
in evanescent carcinoma may reflect the contraction of the tumor 
immune response.
Although, the impact of Treg on HEV is controversial, some 
studies have proposed that Treg affect HEV differentiation 
(53, 54). Thus, given that we found a significant number of Treg 
in TLO from advanced prostate cancer patients, we hypothesized 
that HEV vasculature can be compromised in this particular 
FigUre 7 | Visualization of PD-l1 expression during prostate cancer progression and cancer regression. Prostate sections were stained with antibodies 
against CD3, PD-L1, and CD20. (a) In prostatectomies from patients with prostatic intraepithelial neoplasia (PIN), PD-L1 was expressed by a few cells intermixed 
with T cells. (B,c) At intermediate and advanced stages of prostate cancer, PD-L1+ cells were more numerous and were closely interacting with T cell and B cells. 
(D) PD-L1+ cells were scarce in tertiary lymphoid organs (TLO) from patients with evanescent prostate carcinoma. (e) Few PD-L1+ tumor-infiltrating cells are located 
in close proximity to epithelium in a prostatectomy from a patient with PIN. (F). Although there is still accumulation of T cells close to glandular epithelium, more 
PD-L1+ cells accumulated in tumor areas of intermediate prostate cancer. (g) Considerable accumulation of PD-L1+ cells and lack of T cell infiltrates are seen in 
tumor areas of prostatectomies from advanced cancer patients. (h) A few cells positive for PD-L1 are detected in close proximity to glandular epithelium in samples 
from evanescent prostate carcinoma patients. Representative 200× magnification pictures from TLO and tumor areas were taken with a Zeiss Axioplan Microscope 
and recorded with a Hamamatsu Camera. Yellow scale bar represents 100 µm. Yellow arrows are pointing to PD-L1+ cells with polymorphonuclear-like morphology.
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cohort of cancer patients. We identified HEV and podoplanin+ 
lymphatic vessels in close proximity to B cell follicles (Figures 9C–
F). The presence of lymphatics and HEV in PIN and at all stages 
of prostate cancer progression suggests that mature APC: naïve 
and central memory CD62L+ T cells can be recruited to tumor-
associated TLO. It was also apparent that T cells were providing 
help to B  cells because we were able to detect CD138+ plasma 
cells, which may be actively produced in tumor-associated 
TLO. Supporting the idea that Treg affect the integrity of HEV, 
we found that HEV were significantly smaller in prostatectomy 
specimens from advanced carcinoma patients (285.86 ± 148.40), 
compared to their size in intermediate prostate carcinoma 
FigUre 8 | increased accumulation of regulatory T cells (Treg) in tertiary lymphoid organs (TlO) correlate with cancer progression, while drastic 
enrichment in Tbet+ T cells inside TlO coincides with cancer regression. The 5-µm thick paraffin sections were stained with antibodies against CD3 epsilon, 
Tbet, and Foxp3 to identify CD3+ T cells, CD3+Tbet+ Th1 cells, and CD3+Foxp3+ Treg inside TLO. Representative 400× pictures were taken with a Zeiss Axioplan 
microscope and recorded with a Hamamatsu camera. (a–c) Nuclear Foxp3 (white) and Tbet stain (green) of CD3 T cells (red) reveal a visually apparent 
overrepresentation of CD3+Foxp3+ T cells inside TLO of advanced prostate carcinoma patients. (D) Few Treg intermixed with considerable amounts of CD3+Tbet+ 
T cells are detected in dense T cell areas of TLO from evanescent carcinoma patients. Scale bar represents 100 µm. (e) Percentage of Foxp3+ Treg and (F) 
CD3+Tbet+ in TLO. (g) Ratio between Tbet Th1 cells and Treg was considerably and significantly increased after spontaneous prostate cancer regression. (h) 
Significant correlation between number of Treg and number of TLO was determined by Pearson’s coefficient. Treg inside TLO inversely correlated with a decrease in 
the number of TLO (r2 = 0.8129, p = 0.0183). n = 6–22 200× fields were used to enumerate Tbet+ T cells and Foxp3+ Treg per patient cohort. Differences between 
groups were calculated by using two-tailed, paired or unpaired Student’s t-test, using GraphPad Prism. Bar represent mean ± SEM. Statistically significant 
differences: *p ≤ 0.05, **p ≤ 0.005, ***p ≤ 0.0005, ****p < 0.0001.
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samples (510.60 ± 314.76, p = 0.0178). Interestingly, HEV were 
significantly larger in TLO from patients with evanescent prostate 
carcinoma (660.74 ± 393.82, p = 0.0030), relative to HEV size in 
TLO from advanced carcinoma patients (Figure 9G). However, 
despite that we are proposing Treg are affecting HEV integrity, 
we cannot rule out that tumor microenvironment can affect 
FigUre 9 | accumulation of Dc-laMP+ antigen-presenting cells (aPc) and granzyme B+ cells is associated to reduction in the size of high 
endothelial venules (heV) at late stages of prostate cancer. DC-LAMP+ cells and granzyme B+ cells were enumerated in all the tertiary lymphoid organs (TLO) 
of individual prostatectomy specimens collected at different stages of prostate cancer progression/regression. (a,B) DC-LAMP+ APC and granzyme B+ cells were 
significantly reduced in advanced and evanescent prostate cancer. (c–F) Representative 200× pictures showing location of lymphatics stained with antibodies 
specific for podoplanin (PDPN, white vessels), HEV labeled with antibodies specific for peripheral node addressin (PNAd, red vessels), and CD138+ plasma cells and 
epithelium (green). (g) Progressive reduction in the size of HEV coincides with prostate cancer progression, while recover in HEV size is seen in TLO of patients with 
evanescent prostate cancer. DC-LAMP+ APC and granzyme B+ cells were enumerated in 5–19 200× fields. Scale bars represent 100 µm. Differences between 
groups were calculated with two-tailed, paired, or unpaired Student’s t-test, using GraphPad Prism. Bar represent mean ± SEM. Statistically significant differences: 
*p ≤ 0.05, **p ≤ 0.005, ****p < 0.0001.
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the production of vascular endothelial growth factors by other 
immune cells (DC or B cells) and thus affect HEV growth (55, 56).
Visual estimation of antigen load in 
Prostate Tumors by Detection of Psca
To test whether reduction of granzyme B+ cells correlate with 
changes in tumor antigen load in TLO from advanced and 
evanescent carcinoma patients, we stained prostate sections 
with antibodies against PCNA, PSCA, and plasma cell antigen. 
In lesions from PIN patients, PSCA+ cells inside TLO were rare 
and a few of them had a monocytic morphology (Figure 10A), 
while PSCA+ epithelial cells were scarce and were detected in a few 
tumor areas (Figure 10E). PSCA+ cells were not detectable in TLO 
(Figure 10B), and proliferating epithelial cells labeled with PSCA 
antibodies were detected in some tumor areas from intermediate 
prostate cancer patients (Figure 10F). In patients with advanced 
prostate cancer, few PSCA+ cells were inside TLO (Figure 10C), 
contrasting with the considerable numbers of proliferating 
PSCA+ transformed epithelial cells in tumor areas (Figure 10G). 
As expected, PSCA+ cells were almost absent in TLO and tumor 
areas of samples with evanescent carcinoma (Figures  10D,H). 
Morphometric analysis confirmed our observations and revealed 
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a significantly bigger area covered by PSCA in panoramic pictures 
of prostatectomies from intermediate (830,261.83 ± 267,703.70, 
p  =  0.0020) and advanced prostate cancer patients 
(693,380.42  ±  127,344.12, p  =  0.0002), compared to PIN 
(158,207.25 ± 155,598.37). In sharp contrast, PSCA area was sig-
nificantly reduced in evanescent carcinoma (80,452 ± 36,933.11), 
compared to the area covered by PSCA in intermediate (p = 0.0023) 
and advanced prostate cancer prostatectomies (p  <  0.0001) 
(Figure S2 in Supplementary Material). To confirm that B  cells 
were activated in TLO, prostatectomy specimens were stained 
with antibodies specific for plasma cells. Immunofluorescence 
images revealed the presence of large cells with eccentric nuclei 
in all prostatectomy specimens (Figures 10A,D). Even we found 
a few proliferating plasma cells, which are possibly plasmablasts 
that were recently produced in germinal centers. Altogether, our 
results suggest that antigenic stimulation is taking place in selected 
tumor locations during cancer progression, and that reduction in 
the antigenic load might be linked to destabilization of TLO in 
patients with evanescent prostate carcinoma.
cXcl10 Production by immune cells in 
TlO is critical for Mediating control of 
Tumor cells in TlO areas
Attraction of lymphocytes to TLO is orchestrated by homeostatic 
chemokines (CXCL13, CCL19, CCL21) produced by stromal cell 
populations in the T and B  cell zones (4, 5, 57–59). However, 
based on the increased numbers of Tbet+Th1 cells in TLO from 
patients with evanescent prostate carcinoma, we expected that 
IFNγ, produced by Th1-cells, stimulates local production of 
CXCL10—a chemokine that attracts effector lymphocytes to 
inflammatory sites (60). Thus, we decided to stain sections with 
antibodies against CD3, CXCL10, and smooth muscle actin to 
define the location of CXCL10-producing cells in TLO and tumor 
areas. In PIN samples, we found CD3+ T cells and CD3− immune 
cells positive for CXCL10 in TLO (Figure 11A). Consistent with 
previous reports (61, 62), CXCL10+ epithelial cells were detected 
in a few tumor locations in PIN specimens (Figure  11E). At 
intermediate stages of prostate cancer, a considerable number of 
CXCL10+CD3+ T  cells were located inside TLO (Figure  11B), 
and multiple epithelial cells were positive for CXCL10 in 
tumor areas (Figure 11F). In advanced prostate carcinoma and 
consistent with the reduction in Tbet+ Th1  cells, we noticed a 
reduction in CXCL10+CD3+ T  cells in TLO (Figure  11C) but 
unexplainably observed intense CXCL10 staining in the trans-
formed glandular epithelium (Figure  11G). Finally, we found 
many CD3+ and CD3−CXCL10+ cells in the few and small TLO 
from patients with evanescent prostate carcinoma (Figure 11D), 
contrasting with the scarce and weak expression for CXCL10 
in the glandular epithelium (Figure  11H). Area covered by 
CXCL10+ epithelial cells was significantly larger in intermediate 
(453,886.16 ±  177,813.12, p =  0.0031) and advanced prostate 
cancer patients (713,643.42 ± 242,242.98, p = 0.0003), compared 
to patients with PIN (102,605.8  ±  89,134.77) or evanescent 
carcinoma (64,537.8 ±  52,063.40, Eva Ca vs Int: p =  0.0011, 
Eva Ca vs Adv: p  =  0.0002) (Figure S2 in Supplementary 
Material). Our results suggest that the prostate possesses a unique 
environment that supports the local production of CXCL10, 
which is critical for the attraction of CXCR3+ effector cells to 
tumor-associated TLO.
DiscUssiOn
Here, we show that immune cells infiltrating prostate tumors 
at different stages of cancer progression (PIN, intermediate, 
advanced, and evanescent carcinoma) were organized in com-
plex lymphocytic structures that resemble mature TLO (FDC 
networks, HEV, lymphatics, B cell follicles, T cell areas, mature 
dendritic cells). Given that LTα1β2 expression on B cell and den-
dritic cells is critical for stromal cells differentiation into FDC and 
blood vessels into HEV (63–66), we are assuming that activated 
B cells and dendritic cells are responsible for the morphological 
changes in stromal cells inside tumor-associated TLO (FDC, 
HEV) and for stimulating the local production of homeostatic 
chemokines (CCL19, CCL21, CXCL13) that are key in the attrac-
tion and local activation of immune cells in TLO embedded in 
prostate tumors (67, 68).
Several studies have shown that TLO support protective 
immunity against a variety of pathogens (46, 47, 58) or cause tissue 
damage in inflammatory and autoimmune diseases (15, 69–72). 
Interestingly, presence of TLO in solid tumors correlated with 
a favorable clinical outcome (18, 19). That TLO are detected in 
aggressive tumors suggests that malignant cells are probably able 
to negatively modulate TLO-driven tumor immunity (25, 73). 
Consistent with this idea, our study shows that TLO are present at 
all stages of cancer progression (PIN, intermediate, advance, and 
evanescent carcinoma). This motivated us to perform a detailed 
analysis of tumor environment surrounding TLO with the goal 
of identifying cell or molecular targets that can lead to designing 
personalized therapies focused to enhance TLO functions in 
prostate cancer patients.
We observed a clear reduction in the number and size of 
LF in intermediate and advanced prostate carcinoma patients, 
which is potentially indicating that the tumor suppressive 
microenvironment is exerting a negative pressure on TLO 
formation, organization, and function. Surprisingly, even 
in advanced prostate cancer, we found a few TLO with clear 
evidence of local immune cell activation (FDC networks, HEV, 
B cell, and CD8 T cell proliferation). But the most exciting find-
ing in our study was the reduction in COX2 cell coverage (TLO 
and non-TLO areas), accompanied by the low number of Treg 
and the considerable increase in Tbet+ Th1 cells in TLO from 
unique patients that experienced spontaneous prostate cancer 
regression. This drastic change in the cellular composition of 
tumor-associated TLO in patients with evanescent prostate 
cancer is totally opposite to many of the parameters associated 
with impaired survival in solid cancers (74, 75) and consist-
ent with the positive prognostic value of tumor infiltration by 
Th1 cells (76, 77).
is the Vasculature an appropriate 
Therapeutic Target in Prostate cancer?
It is known that newly formed blood vessels provide nutrients, 
oxygen, and soluble factors for the growth of malignant cells. 
FigUre 10 | increased tumor antigen load and active production of plasma cells are found at late stages of prostate cancer. The 5-µm thick paraffin 
sections were stained with antibodies against proliferating cell nuclear antigen (PCNA) (red), prostate stem cell antigen (PSCA, green), and plasma cell antigen (PC, 
white) to visualize PSCA tumor antigen and plasma cell generation at different stages of cancer progression/regression. Representative 200× pictures were taken 
with a Zeiss Axioplan microscope and recorded with a Hamamatsu camera. (a) Cells with eccentric nuclei (white) and cells positive for PSCA are detected in tertiary 
lymphoid organs (TLO) of prostatic intraepithelial neoplasia (PIN) samples. (B) Plasma cells are detected on the margins of TLO from patients at intermediate stages 
of prostate cancer. (c) Active germinal center that contains proliferating plasma blasts, non-proliferating plasma cells, and PSCA+ cells was found in a sample from a 
patient at advanced stages of prostate cancer. (D) Proliferating plasmablasts are detected in a small TLO from a patient with evanescent prostate carcinoma.  
(e) Low proliferation and scarce PSCA signal in the epithelium of a PIN patient. (F) Highly proliferative but still organized epithelium in a tumor area of a patient at 
intermediate stage of prostate cancer. (g) Disorganized and proliferating nests of epithelial cells in a tumor area of patient with advanced prostate cancer. (h) PSCA 
signal was drastically reduced and epithelium had minimal evidence of proliferation in samples from patients with evanescent prostate cancer. Yellow arrows are 
pointing to proliferating plasmablasts that are indicative of local antigenic stimulation, while white arrows are depicting PSCA+ cells. Scale bar represents 100 µm.
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Indeed, multiple studies have shown that tumor progres-
sion is associated with a global increase in vascularity (78). 
Unexpectedly, we found a reduction in the density of CD105+ 
blood vessels in microenvironments around TLO during 
prostate cancer progression. By sharp contrast, chaotic and 
exuberant neovascularization was increased in areas dominated 
by transformed epithelial cells. Although several groups have 
proposed that CD105 should be targeted to eliminate tumor 
FigUre 11 | immune cells are positive for cXcl10 stain inside tertiary lymphoid organs (TlO), while cXcl10+ epithelial cells are found at tumor 
areas. The 5-µm thick paraffin sections were stained with antibodies against CD3 epsilon (red), CXCL10 (green), and smooth muscle actin (white). Representative 
200× pictures were taken with a Zeiss Axioplan microscope and recorded with a Hamamatsu camera. (a) CXCL10 mainly labels CD3+ T cells inside TLO of 
prostatic intraepithelial neoplasia (PIN) prostatectomy specimens. (B) CXCL10+CD3+ T cells are reduced in TLO of patients with intermediate prostate cancer.  
(c) Immunosuppression in advanced prostate cancer correlates with a drastic reduction in CXCL10+CD3+ T cells inside TLO. (D) CD3+ and CD3−CXCL10+ cells are 
notably increased in small TLO of patients with evanescent prostate carcinoma. (e) CXCL10+ epithelial cells are sporadically found in prostatectomy specimens from 
PIN. (F,g) Intense CXCL10 signal is mainly detected in transformed epithelial cells at intermediate and late stages of prostate cancer. (h) CXCL10+ epithelial cells are 
rarely detected in tumor areas of patients with evanescent prostate carcinoma. Scale bar represents 100 µm.
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blood vessels, there is a potential risk for affecting CD105+ HEV 
and thus impairing recruitment of CD62L+ naïve and central 
memory cells into TLO. Poor recruitment of CD62L+ naïve 
T cells into the prostate tumor could drastically affect the local 
generation of tumor specific T cells that recognize neoantigens, 
which are produced in response to local immune pressure 
and play an important role in immune evasion. In addition, 
disruption of HEV functions will likely prevent recruitment of 
central memory T cells, which have been previously detected in 
the circulation of cancer patients after administration of neo-
adjuvant therapies and that are equipped with potent cytokines 
that kill tumor cells (79). However, it is difficult to know whether 
HEV and lymphatics are providing a functional navigation sys-
tem for APC and T cells inside prostate tumors or whether those 
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specialized vessels are establishing a productive communication 
with draining lymph nodes. Thus, it is encouraging to think that 
instead of targeting the vasculature, we should take advantage 
of HEV and lymphatics already present in prostate tumor-
associated TLO to deliver antigen-loaded mature dendritic 
cells and/or CD62L+ T cells, which will probably accelerate the 
elimination of malignant prostate cells.
Delicate Balance among antigen load, 
inflammation, and immunosuppression 
Dictates the Fate of TlO Organization and 
Function
Several groups have proposed that chronic inflammation 
eventually leads to cancer (80–82). Earlier, Nancy Ruddle’s 
group proposed that chronic inflammation is the driving force 
behind TLO formation (7). Thus, it seems that TLO forma-
tion and organization cannot occur independently of cancer 
development. However, it is anticipated that the suppressive 
microenvironment in prostate tumors will impair TLO organi-
zation and functions. Consistent with the link between chronic 
inflammation and TLO formation, we observed bigger TLO in 
patients with PIN, compared to TLO in patients at intermediate 
and advanced stages of prostate cancer. Also, in agreement with 
previous reports (18), there was a considerable heterogeneity in 
the size and complexity of tumor-associated TLO in prostatec-
tomy specimens. Heterogeneity in TLO may be simply associ-
ated to different phases of TLO organization. Alternatively, 
TLO size and cellular complexity may be linked to the local 
tumor antigen load. In our study, we found indirect evidence of 
lymphocyte activation by local antigens (proliferation of B cell, 
CD8 T cells, plasma cells) in certain areas of prostate tumors 
containing TLO. This possibly means that more immunogenic 
tumor antigens are released in those areas, stimulating lympho-
cytes and thus enhancing TLO organization. Alternatively, TLO 
organization can be affected by accumulation of suppressive 
cells (Treg, myeloid-derived suppressor cells, alternatively acti-
vated macrophages) in the surrounding microenvironment. In 
our study, this dichotomy was clearly exemplified in TLO from 
patients with advanced prostate cancer or spontaneous prostate 
cancer remission. In the context of cancer regression, reduction 
in TLO size correlated with massive decline in PSCA+ cells, 
enrichment in components associated with favorable tumor 
immunity (CD8 T  cell accumulation, increase in HEV size), 
and the considerable reversion of local immunosuppression 
(notable reduction in COX2 cell density and Treg infiltration) 
and tumor neovascularization. By contrast, despite that PSCA 
was highly expressed by epithelial cells in advanced carcinoma 
tumors, the immunosuppressive and protumorigenic environ-
ment (COX2, CD105 neovessels, Treg) was likely overwhelming 
protective immunity generated in TLO. Nevertheless, the pres-
ence of lymphatics and HEV in TLO, even at advanced stages of 
prostate cancer, is indicating that dendritic cell or CD8 T cell-
based therapies could be attractive adjuvant therapies, which 
can exploit the navigation systems of residual TLO to stimulate 
prostate cancer regression. It is also important to consider that 
the potential use of dendritic cells loaded with prostate antigens 
or antigen-specific T  cells poses the risk of causing prostate 
damage. Nonetheless, the feasibility of using these cell therapies 
in humans is supported by preclinical studies of prophylactic 
vaccination with prostate antigens, which induced protective 
tumor immunity without development of detectable autoim-
mune disease (83, 84).
are Treg and cOX2+ inadvertently 
impairing Tumor immunity?
It is well known that Treg are critical in modulating excessive 
inflammation with the purpose of preventing damage to internal 
organs and thus preserving their physiological functions (50). 
For many years, it has been proposed that persistent inflamma-
tion leads to development of cancer (80–82). Thus, despite its 
infamous suppressive role, it is possible that Treg and COX2+ 
cells are simply trying to modulate chronic inflammation in the 
prostate to prevent progression toward malignancy. However, 
they are inadvertently interfering with the induction of tumor 
antigen-driven immune responses in TLO. Thus, a delicate 
balance between effector lymphocytes and Treg must exist in 
tumors to modulate inflammation without affecting protective 
tumor immunity. Although local increase in Treg seems to occur 
with the purpose of preventing local damage in micro-domains 
containing TLO, the tradeoff price is the progressive impairment 
of local tumor immunity, which compromises the life of prostate 
cancer patients.
Prostate has a supportive environment 
for Type 1 immunity
Intriguingly, we confirmed that prostate tumors have permissive 
environments for the induction of type 1 immunity. Especially 
we detected considerable numbers of immune and epithelial 
cells that were producing significant amounts of CXCL10—a 
chemokine with potent angiostatic properties, which is also 
critical to attract CXCR3+ T cells and NK cells (60). One might 
expect that production of CXCL10 by epithelial cells will recruit 
T cell and NK cells to areas of epithelial cell transformation and 
accelerate tumor clearance. However, it has been reported that 
CXCR3A over expression on prostate tumor cells leads to inva-
sion and metastasis (85). Thus, it is possible that during cancer 
progression production of CXCL10 by transformed epithelial 
cells might stimulate tumor metastasis. It is also known that 
COX2 is produced, in response to IFNγ and TNFα stimulation, 
with the purpose of modulating type 1 responses (49). According 
to the strong signal for CXCL10 in transformed epithelial cells, 
it is possible that attraction of CXCR3+ Th1 cells by transformed 
epithelial cells may enhance IFN-dependent production of 
COX2 in tumor areas, enhancing local tumor angiogenesis and 
immunosuppression. In addition, recent reports have shown 
that COX2-dependent production of PGE2 is responsible for 
stimulating PD-L1 expression on myeloid suppressor cells (86). 
Consistent with this idea, we found a considerable increase in 
the accumulation of PD-L1+ cells in tumor areas of patients at 
intermediate and advanced stages of prostate cancer. Thus, it 
seems PGE2 produced by epithelial cells might induce strong 
PD-L1-mediated immunosuppression in tumor areas during 
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prostate cancer progression. Considering that current therapies 
for lung cancer are based in the blockade of PD-L1 to reactivate 
tumor immunity, we are also speculating that due the continu-
ous PGE2-dependent induction of PD-L1 expression on myeloid 
suppressor cells, a synergistic therapy focused on blocking Treg 
and COX2 might be a more powerful approach to reverse immu-
nosuppression in prostate cancer.
One of the limitations of our study was the logistical dif-
ficulty for following up of a larger cohort of prostate cancer 
patients. However, it was clear that although collection of small 
biopsies was sufficient to establish prostate cancer diagnosis and 
prognosis, large prostatectomy specimens were instrumental 
for performing a detailed examination of the molecular and 
cellular changes in different microenvironments of the malig-
nant prostate. We propose that a detailed characterization of 
TLO in prostate tumors might be useful in the near future 
to stratify patients for personalized therapies based on TLO-
associated cellular and molecular signatures. Also, it is possible 
that immune contexture of TLO can be used as a biomarker of 
response to classical therapies such as radiation, chemotherapy, 
and even anti-angiogenic therapies. The expectation is that 
release of tumor antigens by dying tumor cells will potentially 
enhance TLO formation and organization, indicating that 
therapies are making transformed epithelial cells visible for the 
immune system.
It is important to test the relevance of COX2 and Treg in pre-
clinical models before moving to the clinical arena. However, 
we analyzed prostate from transgenic mouse model for prostate 
cancer (TRAMP) mice at various stages of spontaneous cancer 
development, but we did not find TLO (data not shown). A 
future alternative to induce TLO in TRAMP mice might rely 
on increasing local LIGHT expression to attract immune 
cells to prostate tumors (87, 88). Thus, the absence of TLO 
in animal models of prostate cancer complicates the design 
of experimental approaches to mechanistically confirm that 
COX2 and Treg are modulating TLO-driven tumor immunity. 
Nevertheless, we hope that our study can propel the interest 
for performing more retrospective studies with larger numbers 
of prostatectomy specimens, in order to confirm not only the 
association between TLO organization and tumor immunity 
but also to motivate the design of prophylactic or therapeutic 
interventions that take advantage of the already formed TLO 
to prevent progression or induce regression in tumors from 
prostate cancer patients.
In conclusion, our study is showing the dynamic and complex 
interplay that exists among three different processes intertwined 
during cancer progression: (1) induction of TLO by chronic 
inflammation, (2) inflammation-induced cell transformation, 
and (3) establishment of a potent immunosuppressive envi-
ronment that impairs organization and protective functions 
of tumor-associated TLO in prostate cancer. Importantly, 
we detected a considerable increase in COX2 and Treg, two 
well-known players in the modulation of type 1 immunity, 
HEV integrity, and CD8 T  cell accumulation, which are likely 
impacting tumor-associated TLO in prostate cancer. Although 
it is likely that Treg- and COX2-producing cells are perhaps 
trying to prevent inflammation-driven cell transformation and 
prostate damage, we propose that they might also impair local 
tumor immunity. Nevertheless, the risk-benefit of therapies in 
prostate cancer patients should be carefully assessed to decide 
whether induction of tissue damage is better than losing the 
invaluable opportunity for timely delivery of cell-based and/or 
COX2 blocking therapies to reverse tumor immune suppression, 
enhance tumor immunity in TLO, and prolong life expectancy of 
prostate cancer patients.
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FigUre s1 | labeling of proliferating immune cells by antibodies specific 
for Ki-67 and proliferating cell nuclear antigen (Pcna). Consecutive serial 
sections of the same tonsil were stained with antibodies against (a) PCNA, CD8, 
and CD20 or (B) Ki-67, CD8, and CD20. Representative 200× pictures of triple 
immunofluorescent stain for Ki-67, PCNA, and CD20 are shown in (c) prostatic 
intraepithelial neoplasia (PIN), (D) intermediate, (e) advanced, and (F) evanescent 
prostate carcinoma. Germinal centers in tonsils and in a prostatectomy from 
intermediate prostate cancer patients are outlined with white dashed lines. Yellow 
arrows point to proliferating CD20+ B cells. Scale bar represents 100 µm.
FigUre s2 | Measurement of areas covered by cells expressing prostate 
stem cell antigen (Psca) (a) and cXcl10 (B) in prostatectomies. To 
calculate the areas covered by PSCA+ and CXCL10+ cells in panoramic tumor 
areas, 3 × 3 mosaic pictures were taken with the Zeiss Axioplan microscope 
(1.043 mm2). Areas covered by PSCA and CXCL10 in JPGE panoramic pictures 
were blindly measured with NIH ImageJ software. Bar represent mean ± SEM. 
Statistically significant differences: **p ≤ 0.005, ***p ≤ 0.0005.
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